Imperial College London


Faculty of MedicineNational Heart & Lung Institute

Chair of Pulmonary Vascular Diseases



+44 (0)20 7594 6819a.lawrie Website




530ICTEM buildingHammersmith Campus





Allan completed his PhD “The effects of ultrasound on vascular gene delivery” (Supervisor - Prof Chris Newman) in the Department of Cardiovascular Science at the University of Sheffield in 2002. Allan followed this with a post-doctoral position with Prof Marlene Rabinovitch at Stanford University, California where he developed an interest in the molecular mechanisms of Pulmonary Hypertension.

Allan returned to the University of Sheffield in 2004 to establish a translational science research programme in Pulmonary Hypertension. Allan has been successful in obtaining early career and senior Fellowships from the Medical Research Council and British Heart Foundation focused on understanding the role of the osteoprotegerin (OPG) / tumor necrosis factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) axis in PH. Allan also obtained a Medical Research Council DPFS award to co-develop a novel therapeutic antibody targeting OPG for the treatment of pulmonary hypertension. Working closely colleagues in Sheffield all co-launched and Directed the formation of the Donald Heath Centre for Pulmonary Hypertension research. 

Research Interests

Allan moved to the National Heart and Lung Institute at Imperial College London in April 2022 and retains a strong interest in understanding the molecular mechanisms underlying pulmonary hypertension. He retains a firm focus on translation in areas of novel therapies, biomarkers, and the use of ‘Real-World’ data including healthcare and personal activity data to improve early disease diagnosis and monitoring of treatment response. Most recently Allan's research has focused on the utility of artificial intelligence and machine learning (working with Dr Dennis Wang) to help identify molecular sub-groups of patients within current clinical classification groups and aims to identify new molecular classification groups of pulmonary hypertension.

Professional Activities

In addition to serving on grant panels and an active manuscript reviewer all is a Fellow of the Pulmonary Vascular Research Institute and a Trustee of the Board for Scleroderma & Raynaud's UK.



Jackson C, Stewart ID, Plekhanova T, et al., 2023, Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study, The Lancet Respiratory Medicine, ISSN:2213-2600, Pages:1-12

McAuley HJC, Evans RA, Bolton CE, et al., 2023, Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study., Eclinicalmedicine, Vol:57, ISSN:2589-5370, Pages:1-13

Eichstaedt CA, Belge C, Chung WK, et al., 2023, Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH, European Respiratory Journal, Vol:61, ISSN:0903-1936

Carusi A, Winter PDD, Armstrong I, et al., 2023, Medical artificial intelligence is as much social as it is technological, Nature Machine Intelligence

Kheyfets VO, Sweatt AJ, Gomberg-Maitland M, et al., 2023, Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study, Erj Open Research, Vol:9

More Publications